IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sort by
University of Minnesota - Masonic Cancer Center
Minneapolis, MN
- Accepting patients
- Accepting patients
Virginia Cancer Specialists
Fairfax, VA
- Accepting patients
Weill Cornell
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
Stanford University Cancer Institute (Palo Alto)
Stanford, CA
- Not yet accepting
- Not yet accepting
Lifespan Rhode Island Hospital
Providence, RI
- Not yet accepting
- Not yet accepting
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.